المؤلفون: Mirsky MM, Mitchell C, Hong A, Cao S, Fu P, Margevicius S, Wu S, Dowlati A, Nelson A, Selfridge JE, Ramaiya N, Hoimes C, Alahmadi A, Bruno DS

المصدر: Cancer Management and Research, Vol Volume 15, Pp 913-927 (2023)

مصطلحات موضوعية: disparities, healthcare delivery, immunotherapy outcomes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/outcomes-of-antineoplastic-immunotherapy-at-a-large-healthcare-organiz-peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322

URL الوصول: https://doaj.org/article/75615fff5bf448e0a83b2be4fa1ecf10

المؤلفون: Fletcher K., Cortellini A., Ganta T., Kankaria R., Song H., Ye F., Irlmeier R., Debnath N., Saeed A., Radford M., Alahmadi A., Diamond A., Hoimes C., Presley C. J., Owen D. H., Abou Alaiwi S., Nassar A. H., Lamberti G., Perrone F., Buti S., Giusti R., Filetti M., Vanella V., Mallardo D., Sussman T. A., Galetta D., Kalofonou F., Daniels E., Ascierto P. A., Pinato D. J., Nebhan C., Berg S., Choueiri T. K., Marron T. U., Wang Y., Naqash A. R., Johnson D. B.

المساهمون: Fletcher, K., Cortellini, A., Ganta, T., Kankaria, R., Song, H., Ye, F., Irlmeier, R., Debnath, N., Saeed, A., Radford, M., Alahmadi, A., Diamond, A., Hoimes, C., Presley, C. J., Owen, D. H., Abou Alaiwi, S., Nassar, A. H., Lamberti, G., Perrone, F., Buti, S., Giusti, R., Filetti, M., Vanella, V., Mallardo, D., Sussman, T. A., Galetta, D., Kalofonou, F., Daniels, E., Ascierto, P. A., Pinato, D. J., Nebhan, C., Berg, S., Choueiri, T. K., Marron, T. U., Wang, Y., Naqash, A. R., Johnson, D. B.

مصطلحات موضوعية: Anti-PD-1 therapy, Geriatric population, Immune-related adverse event, Immunotherapy, Melanoma

Relation: info:eu-repo/semantics/altIdentifier/pmid/38838764; info:eu-repo/semantics/altIdentifier/wos/WOS:001331314000001; volume:596; journal:CANCER LETTERS; https://hdl.handle.net/11579/202282

الاتاحة: https://hdl.handle.net/11579/202282
https://doi.org/10.1016/j.canlet.2024.217001

المؤلفون: Flaig, T, Hepp, Z, Narayanan, S, Whyte, J, Johnson, N, Matsuda, T, Hoimes, C

المصدر: Value in Health ; volume 25, issue 12, page S400 ; ISSN 1098-3015

الاتاحة: http://dx.doi.org/10.1016/j.jval.2022.09.1988
https://api.elsevier.com/content/article/PII:S1098301522041936?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S1098301522041936?httpAccept=text/plain

المؤلفون: Graff, J.N., Tagawa, S., Hoimes, C., Gerritsen, W., Vaishampayan, U.N., Elliott, T., Hwang, C., Tije, A.J. Ten, Omlin, A.G., McDermott, R.S., De Wit, R., Qiu, P., Poehlein, C., Kim, J., Suttner, L., Cristescu, R., Marton, M.J., Schloss, C., de Bono, J.S., Antonarakis, E.S.

المصدر: Annals of Oncology ; volume 32, page S383 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1016/j.annonc.2021.08.341
https://api.elsevier.com/content/article/PII:S0923753421025709?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753421025709?httpAccept=text/plain

المؤلفون: Beltran H., Oromendia C., Danila D. C., Montgomery B., Hoimes C., Szmulewitz R. Z., Vaishampayan U., Armstrong A. J., Stein M., Pinski J., Mosquera J. M., Sailer V., Bareja R., Romanel A., Gumpeni N., Sboner A., Dardenne E., Puca L., Prandi D., Rubin M. A., Scher H. I., Rickman D. S., Demichelis F., Nanus D. M., Ballman K. V., Tagawa S. T.

المساهمون: Beltran, H., Oromendia, C., Danila, D. C., Montgomery, B., Hoimes, C., Szmulewitz, R. Z., Vaishampayan, U., Armstrong, A. J., Stein, M., Pinski, J., Mosquera, J. M., Sailer, V., Bareja, R., Romanel, A., Gumpeni, N., Sboner, A., Dardenne, E., Puca, L., Prandi, D., Rubin, M. A., Scher, H. I., Rickman, D. S., Demichelis, F., Nanus, D. M., Ballman, K. V., Tagawa, S. T.

Relation: info:eu-repo/semantics/altIdentifier/pmid/30232224; info:eu-repo/semantics/altIdentifier/wos/WOS:000455001100008; volume:25; issue:1; firstpage:43; lastpage:51; numberofpages:9; journal:CLINICAL CANCER RESEARCH; http://hdl.handle.net/11572/240937; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85054925867; https://clincancerres.aacrjournals.org/content/25/1/43

الاتاحة: http://hdl.handle.net/11572/240937
https://doi.org/10.1158/1078-0432.CCR-18-1912
https://clincancerres.aacrjournals.org/content/25/1/43

المؤلفون: Menon, S., Ellis, C., Poudel, S., Johnson, J., Szabo, A., George, B., Kevin Kelly, W., Grant, S., McPherson, J., Cristofanilli, M., Hoimes, C., Gutierrez, M., Doudement, J., Chan, L., Singal, G., Alexander, B., Miller, V., Sohal, D.

المصدر: Journal of Thoracic Oncology ; volume 15, issue 2, page S29-S30 ; ISSN 1556-0864

الاتاحة: http://dx.doi.org/10.1016/j.jtho.2019.12.077
https://api.elsevier.com/content/article/PII:S1556086419337979?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S1556086419337979?httpAccept=text/plain

المؤلفون: Sridhar, S, O'Donnell, P. H, Flaig, T. W, Rosenberg, J. E, Hoimes, C. J, Milowsky, M. I, Srinivas, S., George, S., McKay, R. R, Petrylak, D. P, Coelho Barata, P. M

المصدر: Hematology/Oncology Meeting Abstracts

مصطلحات موضوعية: adjuvant, atezolizumab, cisplatin, enfortumab vedotin, pembrolizumab, rogaratinib, unclassified drug, adult, advanced cancer, adverse drug reaction, antineoplastic activity, bicycle, biomedicine, biotechnology, bladder cancer, cancer adjuvant therapy, cancer patient, cancer staging, cancer surgery, clinical trial, cohort analysis, Colorado, conference abstract, consultation, Corvus, drug combination, drug efficacy, drug safety, drug therapy, drug tolerability

Relation: https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/152; http://sfxhosted.exlibrisgroup.com/hfhs?sid=EMBASE&issn=15698041&id=doi:10.1016%2Fj.annonc.2023.09.1014&atitle=2365MO+Study+EV-103+cohort+L%3A+Perioperative+treatment+w%2F+enfortumab+vedotin+%28EV%29+monotherapy+in+cisplatin+%28cis%29-ineligible+patients+%28pts%29+w%2F+muscle+invasive+bladder+cancer+%28MIBC%29&stitle=Ann.+Oncol.&title=Annals+of+Oncology&volume=34&issue=&spage=S1203&epage=&aulast=Sridhar&aufirst=S.&auinit=S.&aufull=Sridhar+S.&coden=&isbn=&pages=S1203-&date=2023&auinit1=S&auinitm=

الاتاحة: https://scholarlycommons.henryford.com/hematologyoncology_mtgabstracts/152
http://sfxhosted.exlibrisgroup.com/hfhs?sid=EMBASE&issn=15698041&id=doi:10.1016%2Fj.annonc.2023.09.1014&atitle=2365MO+Study+EV-103+cohort+L%3A+Perioperative+treatment+w%2F+enfortumab+vedotin+%28EV%29+monotherapy+in+cisplatin+%28cis%29-ineligible+patients+%28pts%29+w%2F+muscle+invasive+bladder+cancer+%28MIBC%29&stitle=Ann.+Oncol.&title=Annals+of+Oncology&volume=34&issue=&spage=S1203&epage=&aulast=Sridhar&aufirst=S.&auinit=S.&aufull=Sridhar+S.&coden=&isbn=&pages=S1203-&date=2023&auinit1=S&auinitm=

المؤلفون: Talukder R., Makrakis D., Lin G. I., Diamantopoulos L. N., Dawsey S., Gupta S., Carril-Ajuria L., Castellano D., de Kouchkovsky I., Jindal T., Koshkin V. S., Park J. J., Alva A., Bilen M. A., Stewart T. F., McKay R. R., Tripathi N., Agarwal N., Vather-Wu N., Zakharia Y., Morales-Barrera R., Devitt M. E., Cortellini A., Fulgenzi C. A. M., Pinato D. J., Nelson A., Hoimes C. J., Gupta K., Gartrell B. A., Sankin A., Tripathi A., Zakopoulou R., Bamias A., Murgic J., Frobe A., Rodriguez-Vida A., Drakaki A., Liu S., Lu E., Kumar V., Lorenzo G. D., Joshi M., Isaacsson-Velho P., Buznego L. A., Duran I., Moses M., Barata P., Sonpavde G., Wright J. L., Yu E. Y., Montgomery R. B., Hsieh A. C., Grivas P., Khaki A. R.

المساهمون: Talukder, R., Makrakis, D., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., Carril-Ajuria, L., Castellano, D., de Kouchkovsky, I., Jindal, T., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., Mckay, R. R., Tripathi, N., Agarwal, N., Vather-Wu, N., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Cortellini, A., Fulgenzi, C. A. M., Pinato, D. J., Nelson, A., Hoimes, C. J., Gupta, K., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Murgic, J., Frobe, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Lu, E., Kumar, V., Lorenzo, G. D., Joshi, M., Isaacsson-Velho, P., Buznego, L. A., Duran, I., Moses, M., Barata, P., Sonpavde, G., Wright, J. L., Yu, E. Y., Montgomery, R. B., Hsieh, A. C., Grivas, P., Khaki, A. R.

مصطلحات موضوعية: Bladder cancer, Checkpoint Inhibitor, Immunotherapy, Outcome, Platinum resistance

Relation: info:eu-repo/semantics/altIdentifier/pmid/36155169; info:eu-repo/semantics/altIdentifier/wos/WOS:000919659000016; volume:20; issue:6; firstpage:558; lastpage:567; numberofpages:10; journal:CLINICAL GENITOURINARY CANCER; https://hdl.handle.net/11579/159469; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85138769237

الاتاحة: https://hdl.handle.net/11579/159469
https://doi.org/10.1016/j.clgc.2022.08.006

المؤلفون: Talukder R., Makrakis D., Diamantopoulos L. N., Carril-Ajuria L., Castellano D., De Kouchkovsky I., Koshkin V. S., Park J. J., Alva A., Bilen M. A., Stewart T. F., McKay R. R., Santos V. S., Agarwal N., Jain J., Zakharia Y., Morales-Barrera R., Devitt M. E., Grant M., Lythgoe M. P., Pinato D. J., Nelson A., Hoimes C. J., Shreck E., Gartrell B. A., Sankin A., Tripathi A., Zakopoulou R., Bamias A., Murgic J., Frobe A., Rodriguez-Vida A., Drakaki A., Liu S., Kumar V., Lorenzo G. D., Joshi M., Velho P. I., Buznego L. A., Duran I., Moses M., Barata P., Sonpavde G., Yu E. Y., Wright J. L., Grivas P., Khaki A. R.

المساهمون: Talukder, R., Makrakis, D., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., Mckay, R. R., Santos, V. S., Agarwal, N., Jain, J., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Grant, M., Lythgoe, M. P., Pinato, D. J., Nelson, A., Hoimes, C. J., Shreck, E., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Murgic, J., Frobe, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Kumar, V., Lorenzo, G. D., Joshi, M., Velho, P. I., Buznego, L. A., Duran, I., Moses, M., Barata, P., Sonpavde, G., Yu, E. Y., Wright, J. L., Grivas, P., Khaki, A. R.

مصطلحات موضوعية: BCG, Bladder cancer, Immunotherapy, Outcome, Urinary tract neoplasms

Relation: info:eu-repo/semantics/altIdentifier/pmid/35078711; info:eu-repo/semantics/altIdentifier/wos/WOS:000787857300019; volume:20; issue:2; firstpage:165; lastpage:175; numberofpages:11; journal:CLINICAL GENITOURINARY CANCER; https://hdl.handle.net/11579/159438; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85123348408

الاتاحة: https://hdl.handle.net/11579/159438
https://doi.org/10.1016/j.clgc.2021.12.012

المؤلفون: Makrakis D., Talukder R., Lin G. I., Diamantopoulos L. N., Dawsey S., Gupta S., Carril-Ajuria L., Castellano D., de Kouchkovsky I., Koshkin V. S., Park J. J., Alva A., Bilen M. A., Stewart T. F., McKay R. R., Tripathi N., Agarwal N., Vather-Wu N., Zakharia Y., Morales-Barrera R., Devitt M. E., Cortellini A., Fulgenzi C. A. M., Pinato D. J., Nelson A., Hoimes C. J., Gupta K., Gartrell B. A., Sankin A., Tripathi A., Zakopoulou R., Bamias A., Murgic J., Frobe A., Rodriguez-Vida A., Drakaki A., Liu S., Lu E., Kumar V., Lorenzo G. D., Joshi M., Isaacsson-Velho P., Buznego L. A., Duran I., Moses M., Jang A., Barata P., Sonpavde G., Yu E. Y., Montgomery R. B., Grivas P., Khaki A. R.

المساهمون: Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S., Carril-Ajuria, L., Castellano, D., de Kouchkovsky, I., Koshkin, V. S., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., Mckay, R. R., Tripathi, N., Agarwal, N., Vather-Wu, N., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Cortellini, A., Fulgenzi, C. A. M., Pinato, D. J., Nelson, A., Hoimes, C. J., Gupta, K., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Murgic, J., Frobe, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Lu, E., Kumar, V., Lorenzo, G. D., Joshi, M., Isaacsson-Velho, P., Buznego, L. A., Duran, I., Moses, M., Jang, A., Barata, P., Sonpavde, G., Yu, E. Y., Montgomery, R. B., Grivas, P., Khaki, A. R.

مصطلحات موضوعية: Advanced urothelial carcinoma, Bladder cancer, Immune checkpoint inhibitor, Metastatic cancer, Outcomes

Relation: info:eu-repo/semantics/altIdentifier/pmid/35778337; info:eu-repo/semantics/altIdentifier/wos/WOS:001043904500012; volume:20; issue:5; firstpage:440; lastpage:452; numberofpages:13; journal:CLINICAL GENITOURINARY CANCER; https://hdl.handle.net/11579/159421; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85133310824

الاتاحة: https://hdl.handle.net/11579/159421
https://doi.org/10.1016/j.clgc.2022.06.001

المؤلفون: Sadeghi, S., Groshen, S., Parikh, R.A., Mortazavi, A., Dorff, T., Hoimes, C., Doyle, L., Quinn, D.I., Newman, E., Lara, P.

المصدر: Annals of Oncology ; volume 28, page v302 ; ISSN 0923-7534

الاتاحة: http://dx.doi.org/10.1093/annonc/mdx371.014
https://api.elsevier.com/content/article/PII:S0923753420381333?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0923753420381333?httpAccept=text/plain
http://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx371.014/19939712/mdx371.014.pdf

المؤلفون: Galsky M. D., Hoimes C. J., Necchi A., Shore N., Witjes J. A., Steinberg G., Bedke J., Nishiyama H., Fang X., Kataria R., Sbar E., Jia X., Siefker-Radtke A.

المساهمون: Galsky, M. D., Hoimes, C. J., Necchi, A., Shore, N., Witjes, J. A., Steinberg, G., Bedke, J., Nishiyama, H., Fang, X., Kataria, R., Sbar, E., Jia, X., Siefker-Radtke, A.

مصطلحات موضوعية: Antibody-drug conjugate, Immunotherapy, Muscle-invasive bladder cancer, Nectin-4, Pembrolizumab, Perioperative, Programmed death 1, Radical cystectomy

Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000651848200001; volume:17; issue:24; firstpage:3137; lastpage:3150; numberofpages:14; journal:FUTURE ONCOLOGY; http://hdl.handle.net/20.500.11768/118321

الاتاحة: https://hdl.handle.net/20.500.11768/118321
https://doi.org/10.2217/fon-2021-0273

المؤلفون: Nebhan C. A., Cortellini A., Ma W., Ganta T., Song H., Ye F., Irlmeier R., Debnath N., Saeed A., Radford M., Alahmadi A., Diamond A., Hoimes C., Ramaiya N., Presley C. J., Owen D. H., Abou Alaiwi S., Nassar A., Ricciuti B., Lamberti G., Bersanelli M., Casartelli C., Buti S., Marchetti P., Giusti R., Filetti M., Vanella V., Mallardo D., Macherla S., Sussman T. A., Botticelli A., Galetta D., Catino A., Pizzutilo P., Genova C., Dal Bello M. G., Kalofonou F., Daniels E., Ascierto P. A., Pinato D. J., Choueiri T. K., Johnson D. B., Marron T. U., Wang Y., Naqash A. R.

المساهمون: Nebhan, C. A., Cortellini, A., Ma, W., Ganta, T., Song, H., Ye, F., Irlmeier, R., Debnath, N., Saeed, A., Radford, M., Alahmadi, A., Diamond, A., Hoimes, C., Ramaiya, N., Presley, C. J., Owen, D. H., Abou Alaiwi, S., Nassar, A., Ricciuti, B., Lamberti, G., Bersanelli, M., Casartelli, C., Buti, S., Marchetti, P., Giusti, R., Filetti, M., Vanella, V., Mallardo, D., Macherla, S., Sussman, T. A., Botticelli, A., Galetta, D., Catino, A., Pizzutilo, P., Genova, C., Dal Bello, M. G., Kalofonou, F., Daniels, E., Ascierto, P. A., Pinato, D. J., Choueiri, T. K., Johnson, D. B., Marron, T. U., Wang, Y., Naqash, A. R.

مصطلحات موضوعية: Covid-19, cancer

Relation: info:eu-repo/semantics/altIdentifier/pmid/34734989; info:eu-repo/semantics/altIdentifier/wos/WOS:000714699600001; volume:7; issue:12; firstpage:1856; lastpage:1861; numberofpages:6; journal:JAMA ONCOLOGY; http://hdl.handle.net/11573/1603213; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85118984682

الاتاحة: http://hdl.handle.net/11573/1603213
https://doi.org/10.1001/jamaoncol.2021.4960

المؤلفون: Esagian S. M., Khaki A. R., Diamantopoulos L. N., Carril-Ajuria L., Castellano D., De Kouchkovsky I., Park J. J., Alva A., Bilen M. A., Stewart T. F., McKay R. R., Santos V. S., Agarwal N., Jain J., Zakharia Y., Morales-Barrera R., Devitt M. E., Nelson A., Hoimes C. J., Shreck E., Gartrell B. A., Sankin A., Tripathi A., Zakopoulou R., Bamias A., Rodriguez-Vida A., Drakaki A., Liu S., Kumar V., Lythgoe M. P., Pinato D. J., Murgic J., Frobe A., Joshi M., Isaacsson Velho P., Hahn N., Alonso Buznego L., Duran I., Moses M., Barata P., Galsky M. D., Sonpavde G., Yu E. Y., Msaouel P., Koshkin V. S., Grivas P.

المساهمون: Esagian, S. M., Khaki, A. R., Diamantopoulos, L. N., Carril-Ajuria, L., Castellano, D., De Kouchkovsky, I., Park, J. J., Alva, A., Bilen, M. A., Stewart, T. F., Mckay, R. R., Santos, V. S., Agarwal, N., Jain, J., Zakharia, Y., Morales-Barrera, R., Devitt, M. E., Nelson, A., Hoimes, C. J., Shreck, E., Gartrell, B. A., Sankin, A., Tripathi, A., Zakopoulou, R., Bamias, A., Rodriguez-Vida, A., Drakaki, A., Liu, S., Kumar, V., Lythgoe, M. P., Pinato, D. J., Murgic, J., Frobe, A., Joshi, M., Isaacsson Velho, P., Hahn, N., Alonso Buznego, L., Duran, I., Moses, M., Barata, P., Galsky, M. D., Sonpavde, G., Yu, E. Y., Msaouel, P., Koshkin, V. S., Grivas, P.

مصطلحات موضوعية: #uroonc, #utuc, bladder cancer, checkpoint inhibitor, immunotherapy, upper tract urothelial cancer, variant histology

وصف الملف: ELETTRONICO

Relation: info:eu-repo/semantics/altIdentifier/pmid/33556233; info:eu-repo/semantics/altIdentifier/wos/WOS:000615962100001; journal:BJU INTERNATIONAL; http://hdl.handle.net/11579/125793; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85100561925

الاتاحة: http://hdl.handle.net/11579/125793
https://doi.org/10.1111/bju.15324

المؤلفون: Graff, J. N., Tagawa, S. T., Hoimes, C. J., Gerritsen, W. R., Vaishampayan, U. N., Elliott, Tony, Hwang, C., Ten Tije, A. J., Omlin, A., McDermott, R. S., Fradet, Y., Kilari, D., Ferrario, C., Uemura, H., Niu, C. Z., Poehlein, C. H., De Wit, R., Schloss, C., De Bono, J. S., Antonarakis, E. S.

المساهمون: OHSU Knight Cancer Institute, Portland, OR

Relation: https://dx.doi.org/10.1200/JCO.2021.39.15_suppl.5042; Graff JN, Tagawa ST, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, et al. Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study. Vol. 39, Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021. p. 5042–5042.; http://hdl.handle.net/10541/624891; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/624891
https://doi.org/10.1200/JCO.2021.39.15_suppl.5042

المؤلفون: Miller N. J., Khaki A. R., Diamantopoulos L. N., Bilen M. A., Santos V., Agarwal N., Morales-Barrera R., Devitt M., Nelson A., Hoimes C. J., Shreck E., Assi H., Gartrell B. A., Sankin A., Rodriguez-Vida A., Lythgoe M., Pinato D. J., Drakaki A., Joshi M., Isaacsson Velho P., Hahn N., Liu S., Alonso Buznego L., Duran I., Moses M., Jain J., Murgic J., Barata P., Tripathi A., Zakharia Y., Galsky M. D., Sonpavde G., Yu E. Y., Lyman G. H., Grivas P.

المساهمون: Miller, N. J., Khaki, A. R., Diamantopoulos, L. N., Bilen, M. A., Santos, V., Agarwal, N., Morales-Barrera, R., Devitt, M., Nelson, A., Hoimes, C. J., Shreck, E., Assi, H., Gartrell, B. A., Sankin, A., Rodriguez-Vida, A., Lythgoe, M., Pinato, D. J., Drakaki, A., Joshi, M., Isaacsson Velho, P., Hahn, N., Liu, S., Alonso Buznego, L., Duran, I., Moses, M., Jain, J., Murgic, J., Barata, P., Tripathi, A., Zakharia, Y., Galsky, M. D., Sonpavde, G., Yu, E. Y., Lyman, G. H., Grivas, P.

مصطلحات موضوعية: bladder cancer, carcinoma, immunotherapy, neuroendocrine tumor, transitional cell

Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000548744600020; volume:204; issue:1; firstpage:63; lastpage:70; numberofpages:8; journal:THE JOURNAL OF UROLOGY; http://hdl.handle.net/11579/125779; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85086346750

الاتاحة: http://hdl.handle.net/11579/125779
https://doi.org/10.1097/JU.0000000000000761

المؤلفون: Khaki A. R., Li A., Diamantopoulos L. N., Bilen M. A., Santos V., Esther J., Morales-Barrera R., Devitt M., Nelson A., Hoimes C. J., Shreck E., Assi H., Gartrell B. A., Sankin A., Rodriguez-Vida A., Lythgoe M., Pinato D. J., Drakaki A., Joshi M., Isaacsson Velho P., Hahn N., Liu S., Alonso Buznego L., Duran I., Moses M., Jain J., Murgic J., Baratam P., Barata P., Tripathi A., Zakharia Y., Galsky M. D., Sonpavde G., Yu E. Y., Shankaran V., Lyman G. H., Grivas P.

المساهمون: Khaki, A. R., Li, A., Diamantopoulos, L. N., Bilen, M. A., Santos, V., Esther, J., Morales-Barrera, R., Devitt, M., Nelson, A., Hoimes, C. J., Shreck, E., Assi, H., Gartrell, B. A., Sankin, A., Rodriguez-Vida, A., Lythgoe, M., Pinato, D. J., Drakaki, A., Joshi, M., Isaacsson Velho, P., Hahn, N., Liu, S., Alonso Buznego, L., Duran, I., Moses, M., Jain, J., Murgic, J., Baratam, P., Barata, P., Tripathi, A., Zakharia, Y., Galsky, M. D., Sonpavde, G., Yu, E. Y., Shankaran, V., Lyman, G. H., Grivas, P.

مصطلحات موضوعية: bladder cancer, immunotherapy, outcomes research, performance statu, urothelial carcinoma

Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000502160300001; volume:126; issue:6; firstpage:1208; lastpage:1216; numberofpages:9; journal:CANCER; http://hdl.handle.net/11579/125783; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85076443880

الاتاحة: http://hdl.handle.net/11579/125783
https://doi.org/10.1002/cncr.32645

المؤلفون: Vaishampayan, U. N., Elliott, Tony, Omlin, A. G., Graff, J. N., Hoimes, C. J., Tagawa, S. T., Hwang, C., Kilari, D., Ten Tije, A. J., McDermott, R. S., Gerritsen, W. R., Wu, H., Kim, J., Schloss, C., de Bono, J. S., Antonarakis, E. S.

المساهمون: Internal Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA

Relation: https://dx.doi.org/10.1016/j.annonc.2020.10.447; Vaishampayan UN, Elliott T, Omlin AG, Graff JN, Hoimes CJ, Tagawa ST, et al. 227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199. Annals of Oncology. 2020;31:S1330-S.; http://hdl.handle.net/10541/623705; Annals of Oncology

الاتاحة: http://hdl.handle.net/10541/623705
https://doi.org/10.1016/j.annonc.2020.10.447

المؤلفون: Omlin, A. G., Graff, J. N., Hoimes, C. J., Tagawa, S. T., Hwang, C., Kilari, D., Ten Tije, A. J., McDermott, R., Vaishampayan, U. N., Elliott, Tony, Gerritsen, W. R., Wu, H., Kim, J., Schloss, C., de Bono, J. S., Antonarakis, E. S.

المساهمون: Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland

Relation: https://dx.doi.org/10.1016/j.annonc.2020.08.882; Omlin AG, Graff JN, Hoimes CJ, Tagawa ST, Hwang C, Kilari D, et al. 623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update. Annals of Oncology. 2020;31:S514-S5.; http://hdl.handle.net/10541/623504; Annals of Oncology

الاتاحة: http://hdl.handle.net/10541/623504
https://doi.org/10.1016/j.annonc.2020.08.882

المؤلفون: Hoimes, C. J., Graff, J. N., Tagawa, S. T., Hwang, C., Kilari, D., Ten Tije, A. J., Omlin, A., McDermott, R. S., Vaishampayan, U. N., Elliott, Tony, Gerritsen, W. R., Wu, H. Y., Kim, J., Schloss, C., De Bono, J. S., Antonarakis, E. S.

المساهمون: Duke Cancer Institute, Durham, NC

Relation: Hoimes CJ, Graff JN, Tagawa ST, Hwang C, Kilari D, Ten Tije AJ, et al. KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2020;38(15); http://hdl.handle.net/10541/623391; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/623391